should cellular therapies be moved to first line treatment? - blood cancer onctalk
Published 1 year ago • 20 plays • Length 3:40Download video MP4
Download video MP3
Similar videos
-
7:39
car t-cell versus bispecific therapies: how oncologists determine treatment - blood cancer onctalk
-
1:59:57
grace - global resource for advancing cancer education live stream
-
4:11
treatment options for newly diagnosed aml: venetoclax and midostaurin - blood cancer onctalk
-
6:56
what is multiple myeloma? - 2024 blood cancer onctalk
-
5:21
polarix trial and polatuzumab in frontline chemotherapy for dlbcl - 2024 blood cancer onctalk
-
3:14
grace welcome video 2023 blood cancer onctalk
-
1:55
how do i find clinical trials? - blood cancer onctalk
-
9:34
how to treat relapse and choose car t or bispecific antibodies for mm - 2024 blood cancer onctalk
-
3:49
q&a: how do oncologists determine treatment orders? - blood cancer onctalk 2023
-
4:15
treatment timing for multiple myeloma - blood cancer onctalk
-
2:44
approaching treatment for smoldering multiple myeloma - blood cancer onctalk 2023
-
6:28
q&a: should i change my myeloma treatment if i feel healthy? - blood cancer onctalk 2023
-
3:53
the future of bispecific antibodies - blood cancer onctalk 2023
-
5:37
q&a: choosing car t-cell or bispecifics after standard therapy exhaustion- blood cancer onctalk 2023
-
1:44
extended interval dosing for pembrolizumab - lung cancer onctalk 2022
-
6:45
approaches for treatment of multiple myeloma - blood cancer onctalk
-
0:09
blood cancer onctalk 2024 - register now! #shorts #youtubeshorts
-
6:09
upfront bone marrow transplant and maintenance chemotherapy for myeloma - 2024 blood cancer onctalk
-
7:42
novel therapeutics in relapsed setting for diffuse large b-cell lymphoma - 2024 blood cancer onctalk